Author
Listed:
- Krista Dubin
(Infectious Diseases Service, Memorial Sloan Kettering Cancer Center
Lucille Castori Center for Microbes, Inflammation and Cancer, Memorial Sloan Kettering Cancer Center
Weill Cornell Graduate School of Medical Sciences of Cornell University)
- Margaret K. Callahan
(Weill Cornell Medical College
Melanoma and Immunotherapy Service, Memorial Sloan Kettering Cancer Center)
- Boyu Ren
(Harvard School of Public Health)
- Raya Khanin
(Computational Biology Program, Sloan-Kettering Institute)
- Agnes Viale
(Genomics Core Laboratory, Sloan-Kettering Institute)
- Lilan Ling
(Lucille Castori Center for Microbes, Inflammation and Cancer, Memorial Sloan Kettering Cancer Center)
- Daniel No
(Lucille Castori Center for Microbes, Inflammation and Cancer, Memorial Sloan Kettering Cancer Center)
- Asia Gobourne
(Lucille Castori Center for Microbes, Inflammation and Cancer, Memorial Sloan Kettering Cancer Center)
- Eric Littmann
(Lucille Castori Center for Microbes, Inflammation and Cancer, Memorial Sloan Kettering Cancer Center)
- Curtis Huttenhower
(Harvard School of Public Health
Microbial Systems and Communities, Genome Sequencing and Analysis Program, The Broad Institute)
- Eric G. Pamer
(Infectious Diseases Service, Memorial Sloan Kettering Cancer Center
Lucille Castori Center for Microbes, Inflammation and Cancer, Memorial Sloan Kettering Cancer Center
Immunology Program, Sloan-Kettering Institute)
- Jedd D. Wolchok
(Weill Cornell Medical College
Melanoma and Immunotherapy Service, Memorial Sloan Kettering Cancer Center
Immunology Program, Sloan-Kettering Institute
Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center)
Abstract
The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific microbial members of the microbiota is challenging, because clinically detectable inflammation and its treatment can alter the microbiota’s composition. Immunologic checkpoint blockade with ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signalling, is associated with new-onset, immune-mediated colitis. Here we conduct a prospective study of patients with metastatic melanoma undergoing ipilimumab treatment and correlate the pre-inflammation faecal microbiota and microbiome composition with subsequent colitis development. We demonstrate that increased representation of bacteria belonging to the Bacteroidetes phylum is correlated with resistance to the development of checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways involved in polyamine transport and B vitamin biosynthesis is associated with an increased risk of colitis. Identification of these biomarkers may enable interventions to reduce the risk of inflammatory complications following cancer immunotherapy.
Suggested Citation
Krista Dubin & Margaret K. Callahan & Boyu Ren & Raya Khanin & Agnes Viale & Lilan Ling & Daniel No & Asia Gobourne & Eric Littmann & Curtis Huttenhower & Eric G. Pamer & Jedd D. Wolchok, 2016.
"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis,"
Nature Communications, Nature, vol. 7(1), pages 1-8, April.
Handle:
RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms10391
DOI: 10.1038/ncomms10391
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Jonathan W. Lo & Jan-Hendrik Schroeder & Luke B. Roberts & Rami Mohamed & Domenico Cozzetto & Gordon Beattie & Omer S. Omer & Ellen M. Ross & Frank Heuts & Geraldine M. Jowett & Emily Read & Matthew M, 2024.
"CTLA-4 expressing innate lymphoid cells modulate mucosal homeostasis in a microbiota dependent manner,"
Nature Communications, Nature, vol. 15(1), pages 1-17, December.
- Jonathan W. Lo & Domenico Cozzetto & James L. Alexander & Nathan P. Danckert & Matthew Madgwick & Naomi Knox & Jillian Yong Xin Sieh & Marton Olbei & Zhigang Liu & Hajir Ibraheim & Jesus Miguens Blanc, 2023.
"Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis,"
Nature Communications, Nature, vol. 14(1), pages 1-20, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms10391. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.